📰 Oche News
Page 12 - Oche News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Oche. Real-time updates on events, politics, business and more.
October 23, 2023
Roche’s Telavant acquisition comes as the Roivant Sciences subsidiary prepares its main asset for Phase 3 testing in ulcerative colitis. The antibody drug candidate blocks a novel target for inflammation and fibrosis that’s also the focus of clinical-stage programs of other big pharma companies.
October 23, 2023
ZURICH/FRANKFURT (Reuters) -Roche on Monday said it will buy Telavant, a developer of a new treatment for inflammatory bowel diseases, for an initial $7.1 billion from U.S biotech firm Roivant Holdings and Pfizer Inc. Under the deal, which continues Roche's drive to diversify away from its aging cancer treatment business, the Swiss drugmaker will gain the right to develop, manufacture and commercialise an experimental drug known as RVT-3101, in the U.S. and Japan. New Roche CEO Thomas Schin...
October 20, 2023
Prominent lawyer, Akoto Ampaw who represented President Akufo-Addo in the 2020 election petition is reportedly dead.
October 20, 2023
Prominent lawyer, Akoto Ampaw who represented President Akufo-Addo in the 2020 election petition is reportedly dead.
October 20, 2023
The institutions have asked the regulator to delete the programmes from its website ahead of next month’s deadline for the review exercise
October 20, 2023
Lawyer Akoto Ampaw Esq has been reported dead.
October 20, 2023
The death of Akoto Ampaw, one of Ghana’s top legal brains has been announced in Accra. | Pulse Ghana
October 20, 2023
The Ghanaian political and legal landscape has had its fair share of deaths throughout the year, however, the month of October has been one of the saddest months with the passing of some prominent personalities in the country. | Pulse Ghana
October 19, 2023
Paige Tillman talks about her engagement, which was cut from "Love Is Blind" Season 5, and what came next in her relationship with Josh Simmons.
October 19, 2023
Spinal muscular atrophy, a leading genetic cause of infant deaths, prevents the body from producing a protein necessary for neuromuscular development. Royalty Pharma said the agreement with PTC increases its ownership of the Evrysdi royalty from 43% to 81%, equating to a royalty of 6.5% to 13%. The company had in 2020 purchased about 43% of PTC's royalty interest in risdiplam for a one-time payment of $650 million.